Welichem Reports Successful pre-CTA Meeting with Health Canada

    BURNABY, BC, Jan. 26 /CNW/ - Welichem Biotech Inc. (the "Company")
(TSX-V: WBI) is pleased to announce a successful pre-CTA ("Clinical Trial
Application") meeting with the Therapeutic Products Directorate (TPD) of
Health Canada regarding two proposed Phase II clinical studies and a
comprehensive, long-term development plan to enable a marketing application
for WBI-1001 as a topical treatment for psoriasis and atopic dermatitis in
Canada. The purpose of the meeting was to seek guidance and concurrence from
the TPD for the proposed trials and development plan. Prior to this meeting,
the Company submitted, for review by the regulators, a meeting information
package to update the TPD on toxicology/safety and clinical studies conducted
on WBI-1001 to date and on the Company's development plans for this drug
candidate. Health Canada provided feedback and guidance on Welichem's trials
and development plans.

    About Welichem Biotech Inc.

    Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune/inflammatory diseases
and cancer.


    Tan Xiangdong, Chairman of the Board

    The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. This press release contains forward-looking statements that include
our belief as to the potential of our products. Certain risks and
uncertainties such as our ability to successfully commercialize the products
could cause the Company's actual results to differ materially from those in
the forward-looking statements.

    %SEDAR: 00021386E

For further information:

For further information: Genhui Chen, Chief Executive Officer, Tel.:
(604) 432-1703, Email: gchen@welichem.com

Organization Profile

Welichem Biotech Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890